Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease
Introduction: Anti–glomerular basement membrane (GBM) disease is caused by pathogenic antibodies usually targeting the noncollagenous domain of the α3 chain of type IV collagen and frequently presents as rapidly progressive glomerulonephritis and diffuse
Vanja Ivković +15 more
doaj +1 more source
A patient with COVID-19 and anti-glomerular basement membrane disease
Neriman Sila Koc +4 more
doaj +3 more sources
Obinutuzumab in Crescentic Anti-Glomerular Basement Membrane Disease with Linear IgG Deposition: A Case Report. [PDF]
Xue C +7 more
europepmc +1 more source
Complement activation in anti-glomerular basement membrane disease before and after treatment with imlifidase. [PDF]
Tyrberg L +6 more
europepmc +1 more source
Elevated serum soluble α3(IV)NC1 correlates with kidney injury and worse outcome in patients with anti-glomerular basement membrane disease. [PDF]
Kuang H, Wan HS, Cui Z, Zhao MH, Jia XY.
europepmc +1 more source
Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease. [PDF]
Floyd L +19 more
europepmc +1 more source
Serum matrix metalloproteinase-9 levels and enzymatic activity in patients with anti-glomerular basement membrane disease. [PDF]
Kuang H +5 more
europepmc +1 more source
Case Report: Anti-glomerular basement membrane disease during pregnancy with favorable renal outcome, sequential biopsies, and dual anti-α1/α3(IV) and anti-LM521 antibodies. [PDF]
Zhuang J +7 more
europepmc +1 more source

